Journal of Clinical Oncology, Vol 5, 1912-1921, Copyright © 1987 by American Society of Clinical Oncology
Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system
JA Ajani, FL Baker, G Spitzer, A Kelly, W Brock, B Tomasovic, SE Singletary, M McMurtrey and C Plager
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
The newly described adhesive tumor cell culture system (ATCCS) offers a
distinct advantage over other assays in that it has a high plating
efficiency requiring low cell inoculum, it affords workable assays in
approximately 70% of specimens from the heterogenous tumor types, and it
has the ability to assay up to nine drugs at four different concentrations.
Clinical correlations based on the ATCCS were obtained in 65 patients
undergoing 71 clinical trials. Patients with melanoma, lung cancer, and
sarcoma dominated the group. The most active in vitro drug was correlated
per clinical trial. Thirteen of 17 (76%) sensitive in vitro predictions and
51 of 54 (94%) resistant in vitro predictions were accurate. The assay in
this study had a sensitivity of 81% and specificity of 93%. These
preliminary results are encouraging and warrant prospective trials to
establish the true value of this assay to patients.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
